{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-025573","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2025-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.399307+00:00","generated_at":"2026-05-21T09:02:29.631079+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"AbCellera gets Health Canada nod for Phase 1 trial of ABCL635 for hot flashes","bullets":["Received No Objection Letter from Health Canada for ABCL635, an NK3R antagonist for non-hormonal treatment of vasomotor symptoms.","Phase 1 trial to evaluate safety, PK, and PD in healthy participants and postmenopausal women with moderate-to-severe VMS.","Trial expected to begin in Q3 2025.","ABCL635 is an investigational antibody antagonist targeting NK3R, developed for hot flashes due to menopause."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-025573","json":"https://secwatch.observer/filing/0001628280-25-025573.json","markdown":"https://secwatch.observer/filing/0001628280-25-025573.md","text":"https://secwatch.observer/filing/0001628280-25-025573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000162828025025573/0001628280-25-025573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000162828025025573/abcl-20250514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T09:02:29.631079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}